4.7 Article

Hydration of an amphiphilic excipient, Gelucire® 44/14

Journal

INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 281, Issue 1-2, Pages 107-118

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2004.06.005

Keywords

Gelucireo((R)) 44/14; phrase diagram; hydration; dissolution; mesophases; PEG esters; DVS; SAXS; WAXS

Ask authors/readers for more resources

The incorporation of drugs into Gelucires has been reported to increase the dissolution rate of poorly soluble drugs, often leading to improved drug bioavailability. In pharmaceutical applications, it is important to know how the excipient interacts with the drug, and how the mixture behaves during manufacturing, storage as well as during administration. The uptake of water by an amphiphilic excipient, Gelucire(R) 44/14, has been investigated in two ways: storage in humid air and addition of liquid water. During exposure to humid air, the uptake goes in stages that correspond to the dissolution of the components of the excipient, starting with the most hydrophilic ones: glycerol, then polyethylene glycol (PEG), PEG esters (PEG monolaurate and PEG dilaurate), and finally glycerides (trilaurin). At each stage, the remaining: crystals are in equilibrium with an interstitial solution made of water and the dissolved components. In this range of hydrations, the total uptake is close to the sum of the equilibrium hydrations of the components. In the pharmaceutical formulation, the active ingredient could dissolve in the liquid phase. At larger hydrations obtained through addition of liquid water, the state of Gelucire(R) 44/14 differs from those of its components. Gelucire(R) 44/14 forms a lamellar phase and this phase melts at 30degreesC whereas the pure PEG esters form hexagonal and cubic mesophases. The cubic mesophases do not melt until the temperature exceeds 40degreesC. At body temperature, all crystals in Gelucire(R) 44/14 melt to an isotropic fluid as soon as the total water content exceeds 5%. Therefore the formulation of amphiphilic excipients can be optimized to avoid the formation of mesophases that impede dissolution of the excipient at body temperature. (C) 2004 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available